Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vedolizumab vs placebo SF‐36 PCS at week 6 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 1 study · 374 participants | Moderate |
Vedolizumab vs placebo SF‐36 MCS at week 6 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 1 study · 374 participants | Moderate |
Vedolizumab vs placebo SF‐36 PCS at week 52 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 1 study · 248 participants | Moderate |
Vedolizumab vs placebo SF‐36 MCS at week 52 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 1 study · 248 participants | Moderate |
TNF‐alpha antagonists vs placebo Improved IBDQ at weeks 6 or 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | RR 1.32 [1.19, 1.46] | 3 studies · 1495 participants | High |
Rituximab vs placebo IBDQ at week 12 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
TNF‐alpha antagonists vs placebo IBDQ at weeks 6 or 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 4 studies · 1565 participants | Moderate |
Infliximab vs placebo Improved IBDQ at week 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | RR 1.39 [1.21, 1.6] | 1 study · 728 participants | High |
Infliximab vs placebo IBDQ at week 6 or 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 2 studies · 529 participants | High |
Infliximab vs placebo EQ‐5D at week 6 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
Infliximab vs placebo Improved SF‐36 PCS at week 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | RR 1.51 [1.23, 1.85] | 1 study · 728 participants | Moderate |
Infliximab vs placebo Improved SF‐36 MCS at week 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | RR 1.44 [1.16, 1.79] | 1 study · 728 participants | Moderate |
Adalimumab vs placebo Improved IBDQ at week 8 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | RR 1.23 [1.06, 1.43] | 2 studies · 767 participants | Moderate |
Adalimumab vs placebo Improved IBDQ at week 52 · patients with active ulcerative colitis The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane | RR 1.73 [1.28, 2.34] | 2 studies · 767 participants | Moderate |
Stapler vs scalpel resection followed by hand‐sewn closure of the pancreatic remnant Postoperative Pancreatic Fistula · patients with distal pancreatectomy Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal… (2015) · Cochrane | RR 0.9 [0.55, 1.45] | 2 studies · 381 participants | Moderate |
Stapler vs scalpel resection followed by hand‐sewn closure of the pancreatic remnant Mortality · patients with distal pancreatectomy Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal… (2015) · Cochrane | RR 0.49 [0.05, 5.4] | 2 studies · 381 participants | Moderate |
Stapler vs scalpel resection followed by hand‐sewn closure of the pancreatic remnant Operation Time · patients with distal pancreatectomy Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal… (2015) · Cochrane | no estimate extracted | 2 studies · 381 participants | Moderate |
Drain vs no drain 30‐day mortality Death during the · gastric cancer Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer (2015) · Cochrane | RR 1.73 [0.38, 7.84] | 4 studies · 438 participants | Very low |
Drain vs no drain Post‐operative complications · gastric cancer Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer (2015) · Cochrane | no estimate extracted | 0 studies · 4 participants | Low |
Drain vs no drain Re‐operations Re‐operations during the · gastric cancer Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer (2015) · Cochrane | RR 2.49 [0.71, 8.74] | 2 studies · 230 participants | Very low |
Drain vs no drain Operation time The time from the start to the end of operation. Scale from: 0 to 100. · gastric cancer Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer (2015) · Cochrane | no estimate extracted | 3 studies · 378 participants | Low |
Drain vs no drain Length of post‐operative hospital stay The time from the day of operation to the day of discharge. Scale from: 0 to 100. · gastric cancer Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer (2015) · Cochrane | no estimate extracted | 4 studies · 438 participants | Low |
Immunonutrition vs control All‐cause mortality · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.49 [0.29, 0.8] | 6 studies · 520 participants | Low |
Immunonutrition with probiotics and fibres vs control All‐cause mortality · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Immunonutrition with probiotics and fibres vs control Systemic inflammatory response syndrome ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Immunonutrition with probiotics and fibres vs control Organ failure ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Immunonutrition with probiotics and fibres vs control Adverse events ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Semi‐elemental enteral nutrition vs control All‐cause mortality · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Semi‐elemental enteral nutrition vs control Systemic inflammatory response syndrome ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Semi‐elemental enteral nutrition vs control Organ failure ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Semi‐elemental enteral nutrition vs control Adverse events ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Fibre‐enriched enteral nutrition vs control All‐cause mortality · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.23 [0.03, 1.84] | 2 studies · 103 participants | Very low |
Fibre‐enriched enteral nutrition vs control Systemic inflammatory response syndrome · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 1.03 [0.94, 1.13] | 1 study · 60 participants | Very low |
Immunonutrition vs control Systemic inflammatory response syndrome · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 1 [0.76, 1.31] | 3 studies · 278 participants | Low |
Fibre‐enriched enteral nutrition vs control Organ failure · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.86 [0.73, 1.01] | 1 study · 60 participants | Very low |
Fibre‐enriched enteral nutrition vs control Adverse events ‐ not reported · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Enteral nutrition vs no intervention All‐cause mortality · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.5 [0.29, 0.86] | 4 studies · 511 participants | Low |
Enteral nutrition vs no intervention Systemic inflammatory response syndrome · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.94 [0.7, 1.26] | 1 study · 214 participants | Very low |
Enteral nutrition vs no intervention Organ failure · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.81 [0.52, 1.26] | 1 study · 214 participants | Very low |
Enteral nutrition vs no intervention Adverse events · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 9 [0.49, 165.14] | 1 study · 214 participants | Very low |
Immunonutrition vs control Organ failure · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.75 [0.49, 1.13] | 4 studies · 290 participants | Low |
Immunonutrition vs control Adverse events · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 1.32 [0.78, 2.24] | 4 studies · 294 participants | Very low |
Probiotics vs control All‐cause mortality · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 1.13 [0.66, 1.91] | 6 studies · 666 participants | Very low |
Probiotics vs control Systemic inflammatory response syndrome · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 1.07 [0.9, 1.27] | 3 studies · 223 participants | Very low |
Probiotics vs control Organ failure · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 0.84 [0.67, 1.04] | 5 studies · 644 participants | Very low |
Probiotics vs control Adverse events · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 1.18 [0.33, 4.2] | 2 studies · 133 participants | Low |
Probiotics vs control Serious adverse events · patients with acute pancreatitis Enteral nutrition formulations for acute pancreatitis (2015) · Cochrane | RR 17.89 [1.05, 304.59] | 1 study · 298 participants | Very low |
Etrolizumab vs placebo Failure to enter clinical remission at week 10 · patients with induction of remission in ulcerative colitis Etrolizumab for induction of remission in ulcerative colitis (2015) · Cochrane | RR 0.86 [0.77, 0.95] | 1 study · 119 participants | Moderate |
Etrolizumab vs placebo Failure to enter clinical remission at week 10 ‐ 100 mg · patients with induction of remission in ulcerative colitis Etrolizumab for induction of remission in ulcerative colitis (2015) · Cochrane | RR 0.81 [0.68, 0.96] | 1 study · 59 participants | Moderate |
Etrolizumab vs placebo Failure to respond at week 10 · patients with induction of remission in ulcerative colitis Etrolizumab for induction of remission in ulcerative colitis (2015) · Cochrane | RR 0.96 [0.75, 1.23] | 1 study · 119 participants | Moderate |